Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy - 1 Oct 2014

Sim Geok Choo, Chacon Jessica, Haymaker Cara, Ritthipichai Krit, Singh Manish, Hwu Patrick, Radvanyi Laszlo

Abstract excerpt

Cancer immunotherapy has become an important area for the future development of cancer therapy; this includes T-cell-based therapies that involve adoptive transfer of autologous T cells derived from the tumors or peripheral blood of cancer patients, vaccines, oncolytic virus therapy, and immunomodulatory antibodies and ligands. Here, we summarize the current approaches and clinical data in the field of adoptive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Biomarkers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Genes, Neoplasm

Share to Immunotherapy, Adoptive

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma

Share to Neoplasm Metastasis

Source

Identifiers

PMID: 24890028
DOI: 10.1007/s40259-014-0097-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.PMID 24890028Read ↗

T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.Semantic proximity Read ↗

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.Semantic proximity Read ↗

Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignanciesSemantic proximity Read ↗

Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive ReviewSemantic proximity Read ↗

Melanoma Treatments: Advances and Mechanisms.Semantic proximity Read ↗

Adoptive T-Cell Therapy for Cancer.Semantic proximity Read ↗

Long-term efficacy of adoptive cell therapy is determined by host CD8 <sup>+</sup> T cells and undermined by lymphodepleting preconditioningSemantic proximity Read ↗

T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studiesSemantic proximity Read ↗

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.Semantic proximity Read ↗

Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.Semantic proximity Read ↗

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.Semantic proximity Read ↗

Exploiting the curative potential of adoptive T‐cell therapy for cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.